[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
ONLINE FIRST
November 14, 2012

Does Antiviral Therapy Prevent Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Curative Liver Resection?

Author Affiliations

Author Affiliations: Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor.

JAMA. 2012;308(18):1922-1924. doi:10.1001/jama.2012.12971

Surgical resection and liver transplantation are the only curative therapies for hepatocellular carcinoma (HCC); however, fewer than 20% of patients are eligible for these therapies.1 Surgical resection is the treatment of choice for HCC in patients with a solitary tumor and no evidence of cirrhosis; this disease pattern accounts for roughly 5% of HCC in western countries and 40% in Asia.1 The higher percentage of HCC patients in Asia who are amenable to surgical resection is related to the predominance of hepatitis B virus (HBV)–related HCC, which can occur in the absence of cirrhosis. Improvement in early diagnosis of HCC and more accurate evaluation of underlying liver function have resulted in 5-year survival after resection for HCC exceeding 50%.1 Nevertheless, despite careful selection, HCC recurrence rate after surgical resection is high: 50% to 70% at 5 years.1 None of the adjuvant therapies prior to or immediately following resection have been shown to reduce the rate of HCC recurrence.

First Page Preview View Large
First page PDF preview
First page PDF preview
×